AMD3100 Inhibits Mesenchymal Stem Cell Recruitment to Treat Tumor Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for addressing tumor cachexia, a common and debilitating symptom in cancer patients characterized by involuntary weight loss and muscle wasting, which complicates tumor treatment and reduces quality of life.
Innovation Solution
The use of AMD3100 or its pharmaceutically acceptable salt to block the recruitment of mesenchymal stem cells by tumors, thereby maintaining tissue homeostasis and alleviating cachexia symptoms, is proposed. This involves administering AMD3100 via injection, potentially in combination with other drugs, to inhibit the migration of Nestin+ mesenchymal stem cells to tumor sites, thus reducing cachexia symptoms and improving treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional nutritional support and exercises are used to treat tumor cachexia, then patient survival is extended, but the treatment effect is insufficient and quality of life is not significantly improved
Solution Approach 1:
The patent changes the therapeutic parameter from traditional nutritional support to AMD3100 pharmacological intervention. AMD3100 blocks the CXCR4 receptor, preventing mesenchymal stem cell migration to tumor sites, thereby fundamentally altering the pathogenesis of cachexia rather than merely supporting symptoms
Solution Approach 2:
The patent extracts and targets the specific mechanism of mesenchymal stem cell recruitment to tumor sites via CXCR4 receptor activation. By blocking this specific pathway with AMD3100, the treatment isolates and addresses the core pathological mechanism rather than treating general symptoms
2Object-generated harmful factors
If mesenchymal stem cells are recruited by tumors, then tumor growth is supported, but tissue homeostasis is destroyed and cachexia occurs
Solution Approach 1:
The patent introduces AMD3100 as an intermediary substance that blocks the interaction between tumor-derived CXCL12 and mesenchymal stem cell CXCR4 receptors. This mediator prevents the harmful recruitment process while preserving normal tissue homeostasis
Solution Approach 2:
The patent converts the harmful CXCL12-CXCR4 signaling pathway into a beneficial blocked state. By inhibiting this pathway, the treatment prevents mesenchymal stem cell migration to tumors, thereby converting a pro-tumor mechanism into a protective effect that maintains tissue homeostasis
Data Source
Figure 1A~1D
Figure 2A~2F
Figure 3A~4
AI summary
The disclosure relates to use of AMD3100 or a pharmaceutically acceptable salt thereof in preparation of a drug for treatment and/or prevention of dyscrasia and a pharmaceutical composition thereof as well as a method for treating and/or preventing dyscrasia using the same.